Seamus Fernandez
Stock Analyst at Guggenheim
(4.17)
# 447
Out of 4,944 analysts
106
Total ratings
50%
Success rate
15.3%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Buy | $942 → $875 | $646.48 | +35.35% | 18 | Aug 13, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $92 → $90 | $18.99 | +373.93% | 2 | Aug 7, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $119 → $120 | $96.09 | +24.88% | 2 | Aug 6, 2025 | |
| APGE Apogee Therapeutics | Reiterates: Buy | $116 | $36.70 | +216.08% | 8 | Jul 2, 2025 | |
| CDTX Cidara Therapeutics | Maintains: Buy | $50 → $68 | $60.84 | +11.77% | 4 | Jun 24, 2025 | |
| AMLX Amylyx Pharmaceuticals | Initiates: Buy | $17 | $8.16 | +108.33% | 1 | Jun 24, 2025 | |
| MBX MBX Biosciences | Reiterates: Buy | $44 | $12.63 | +248.38% | 2 | Apr 10, 2025 | |
| ARQT Arcutis Biotherapeutics | Reiterates: Buy | n/a | $14.89 | - | 3 | Apr 3, 2025 | |
| PCVX Vaxcyte | Reiterates: Buy | $160 | $30.28 | +428.40% | 4 | Mar 12, 2025 | |
| MTSR Metsera | Initiates: Buy | $56 | $31.48 | +77.89% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $12.94 | - | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $122 | $80.74 | +51.10% | 14 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $38.64 | - | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $5.80 | +175.86% | 1 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.06 | - | 3 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.61 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $15.26 | - | 2 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $46.58 | - | 12 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $50.39 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $120.05 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.17 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $1.64 | +3,192.68% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $24.16 | +86.26% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $76.89 | -50.58% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $24.77 | +53.41% | 3 | Jan 31, 2018 |
Eli Lilly and Company
Aug 13, 2025
Maintains: Buy
Price Target: $942 → $875
Current: $646.48
Upside: +35.35%
Structure Therapeutics
Aug 7, 2025
Maintains: Buy
Price Target: $92 → $90
Current: $18.99
Upside: +373.93%
Rhythm Pharmaceuticals
Aug 6, 2025
Maintains: Buy
Price Target: $119 → $120
Current: $96.09
Upside: +24.88%
Apogee Therapeutics
Jul 2, 2025
Reiterates: Buy
Price Target: $116
Current: $36.70
Upside: +216.08%
Cidara Therapeutics
Jun 24, 2025
Maintains: Buy
Price Target: $50 → $68
Current: $60.84
Upside: +11.77%
Amylyx Pharmaceuticals
Jun 24, 2025
Initiates: Buy
Price Target: $17
Current: $8.16
Upside: +108.33%
MBX Biosciences
Apr 10, 2025
Reiterates: Buy
Price Target: $44
Current: $12.63
Upside: +248.38%
Arcutis Biotherapeutics
Apr 3, 2025
Reiterates: Buy
Price Target: n/a
Current: $14.89
Upside: -
Vaxcyte
Mar 12, 2025
Reiterates: Buy
Price Target: $160
Current: $30.28
Upside: +428.40%
Metsera
Feb 25, 2025
Initiates: Buy
Price Target: $56
Current: $31.48
Upside: +77.89%
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $12.94
Upside: -
Jan 17, 2025
Maintains: Buy
Price Target: $130 → $122
Current: $80.74
Upside: +51.10%
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $38.64
Upside: -
Oct 14, 2024
Initiates: Buy
Price Target: $16
Current: $5.80
Upside: +175.86%
Jul 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.06
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.61
Upside: -
Jul 14, 2023
Maintains: Buy
Price Target: n/a
Current: $15.26
Upside: -
Oct 10, 2022
Downgrades: Neutral
Price Target: n/a
Current: $46.58
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $50.39
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $120.05
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $7.17
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $1.64
Upside: +3,192.68%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $24.16
Upside: +86.26%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $76.89
Upside: -50.58%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $24.77
Upside: +53.41%